계명대학교 의학도서관 Repository

Safety of 3-Month Dual Antiplatelet Therapy After Implantation of Ultrathin Sirolimus-Eluting Stents With Biodegradable Polymer (Orsiro): Results From the SMART-CHOICE Trial

Metadata Downloads
Author(s)
Kyeong Ho YunSeung-Yul LeeByung Ryul ChoWoo Jin JangYoung Bin SongJu-Hyeon OhWoo Jung ChunYong Hwan ParkEul-Soon ImJin-Ok JeongSeok Kyu OhDeok-Kyu ChoJong-Young LeeYoung-Youp KohJang-Whan BaeJae Woong ChoiWang Soo LeeHyuck Jun YoonSeung Uk LeeJang Hyun ChoWoong Gil ChoiSeung-Woon RhaJoo Myung LeeTaek Kyu ParkJeong Hoon YangJin-Ho ChoiSeung-Hyuck ChoiSang Hoon LeeHyeon-Cheol GwonJoo-Yong Hahn
Keimyung Author(s)
Yoon, Hyuck Jun
Department
Dept. of Internal Medicine (내과학)
Journal Title
Journal of the American Heart Association
Issued Date
2021
Volume
10
Issue
1
Keyword
antiplatelet therapycoronary artery diseasepercutaneous coronary intervention
Abstract
Background:
This study sought to investigate the safety of 3‐month dual antiplatelet therapy (DAPT) in patients receiving ultrathin sirolimus‐eluting stents with biodegradable polymer (Orsiro).

Methods and Results:
The SMART‐CHOICE (Smart Angioplasty Research Team: Comparison Between P2Y12 Antagonist Monotherapy vs Dual Anti‐ platelet Therapy in Patients Undergoing Implantation of Coronary Drug‐Eluting Stents) randomized trial compared 3‐month DAPT followed by P2Y12 inhibitor monotherapy with 12‐month DAPT in 2993 patients undergoing percutaneous coronary intervention. The present analysis was a prespecified subgroup analysis for patients receiving Orsiro stents. As a post hoc analysis, comparisons between Orsiro and everolimus‐eluting stents were also done among patients receiving 3‐month DAPT. Of 972 patients receiving Orsiro stents, 481 patients were randomly assigned to 3‐month DAPT and 491 to 12‐month DAPT. At 12 months, the target vessel failure, defined as a composite of cardiac death, target vessel–related myocardial infarction, or target vessel revascularization, occurred in 8 patients (1.7%) in the 3‐month DAPT group and in 14 patients (2.9%) in the 12‐month DAPT group (hazard ratio [HR], 0.58; 95% CI, 0.24–1.39; P=0.22). In whole population who were randomly assigned to receive 3‐month DAPT (n=1495), there was no significant difference in the target vessel failure between the Orsiro group and the everolimus‐eluting stent group (n=1014) (1.7% versus 1.8%; HR, 0.96; 95% CI, 0.41–2.22; P=0.92).

Conclusions:
In patients receiving Orsiro stents, clinical outcomes at 1 year were similar between the 3‐month DAPT followed by P2Y12 inhibitor monotherapy and 12‐month DAPT strategies. With 3‐month DAPT, there was no significant difference in target vessel failure between Orsiro and everolimus‐eluting stents.
Keimyung Author(s)(Kor)
윤혁준
Publisher
School of Medicine (의과대학)
Citation
Kyeong Ho Yun et al. (2021). Safety of 3-Month Dual Antiplatelet Therapy After Implantation of Ultrathin Sirolimus-Eluting Stents With Biodegradable Polymer (Orsiro): Results From the SMART-CHOICE Trial. Journal of the American Heart Association, 10(1), e018366. doi: 10.1161/JAHA.120.018366
Type
Article
ISSN
2047-9980
Source
https://www.ahajournals.org/doi/10.1161/JAHA.120.018366
DOI
10.1161/JAHA.120.018366
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/43452
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.